The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Improving patient outcomes in relapsed/refractory lung cancer
Liza Villaruz, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, discusses unmet needs in non-small cell lung cancer (NSCLC), including the need to optimize patient selection for therapies. Whilst there has been advances in targeted therapies and immunotherapies, utilizing biomarkers will help identify patients who will benefit from treatment the most. Molecular stratification of patients was proven to be beneficial in the Phase II HUDSON study (NCT03334617) , which assessed the ATR inhibitor durvalumab, and preclinical data has additionally shown bemcentinib, an AXL inhibitor, to be efficacious in patients with STK11-mutant lung cancer. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC22).
